Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATF4 | P18848 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CBS | P35520 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809034 | 0.88 | ATF4 (0.42) | ITGB3ITGA2BPTGIRPRMT5WDR77 | |
| SCHEMBL1809033 | 0.88 | ATF4 (0.42) | ITGB3ITGA2BPTGIRPRMT5WDR77 | |
| SCHEMBL9194978 | 0.84 | — | — | |
| SCHEMBL8893566 | 0.83 | PRMT5 (0.34) | PRMT5WDR77L3MBTL1ELANEATF4 | |
| SCHEMBL23386552 | 0.81 | PIK3CD (0.37) | PRMT5WDR77L3MBTL1ELANEATF4 | |
| SCHEMBL24158596 | 0.81 | KDM4E (0.36) | PRMT5WDR77L3MBTL1ELANEATF4 | |
| SCHEMBL360541 | 0.79 | ITGB3 (0.41) | ITGB3ITGA2BPTGIRATF4TSHR | |
| SCHEMBL1733927 | 0.79 | — | — | |
| SCHEMBL8105483 | 0.78 | ELANE (0.35) | PRMT5WDR77ELANEATF4SPHK1 | |
| SCHEMBL24564741 | 0.77 | THRA (0.42) | ITGB3ITGA2BPTGIRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-114867530-B | MCL1 inhibitors | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0763042-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | Novartis AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| EP-0532178-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995032976-A1 | POLYCYCLIC LACTAM DERIVATIVES FOR SENSITIZING MULTIDRUG-RESISTANT CELLS TO ANTITUMOUR AGENTS | CIBA-GEIGY AG (CH) | 1995-12-07 | — | — | WO | disclosed |
| US-5455241-A | Staurosporin derivatives as enzyme inhibitors for protein kinase C and platelet-derived growth factor kinase; antitumor agents, bactericides, antigrowth agents | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| US-5455246-A | Treating neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-10-03 | — | — | US | disclosed |
| US-5382675-A | Staurosporin intermediates | CIBA-GEIGY CORPORATION (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | ITGB3 2784/4885ITGA2B 3155/4885PTGIR 2915/4885 |
| US-12202842-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | ITGB3 2661/4885ITGA2B 2481/4885PTGIR 2768/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | ITGB3 2642/4885ITGA2B 2468/4885PTGIR 2684/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | ITGB3 2642/4885ITGA2B 2468/4885PTGIR 2684/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | ITGB3 2642/4885ITGA2B 2468/4885PTGIR 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.